

# Development of therapeutic antibody for the treatment of myasthenia gravis



NEUROSCIENCE	Candidate
Product Type	Antibody
Indication	Generalized myasthenia gravis
Target	Disclosure after confidentiality agreement
MoA(Mechanism of Action)	Disclosure after confidentiality agreement
Competitiveness	<ul style="list-style-type: none"> <li>• Novel and simple MoA.</li> <li>• No inhibition of body's immune system.</li> <li>• Easy and fast administration.</li> <li>• Long injection intervals.</li> <li>• Applicable even to patients refractory to complement inhibitors</li> </ul>
Development Stage	Candidate
Route of Administration	Subcutaneous